[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100264264":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":11,"centralContacts":11,"locations":23,"responsibleParty":35,"collaborators":11,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":11,"acronym":11,"eligibilityCriteria":42,"healthyVolunteers":43,"sex":44,"minAge":45,"maxAge":46,"enrollmentInfo":47,"targetDuration":11,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":11,"overallStatus":56,"whyStopped":11,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},{"fullName":5,"class":6},"Kowa Research Institute, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Warfarin\u002FWarfarin + K-877","OTHER",null,[13,14],"Drug: Warfarin","Drug: K-877",[16,20],{"type":17,"name":18,"description":11,"armGroupLabels":19,"otherNames":11},"DRUG","Warfarin",[9],{"type":17,"name":21,"description":11,"armGroupLabels":22,"otherNames":11},"K-877",[9],[24],{"facility":11,"status":11,"city":25,"state":26,"zip":11,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":11},"Austin","Texas","United States","US",{"type":30,"coordinates":31},"Point",[32,33],-97.74306,30.26715,{"lat":33,"lon":32},{"type":36,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100264264","phase-1-drug-drug-interaction-study-to-assess-the-effects-of-multiple-dose-administration-of-k-877-on-the-pharmacodynamics-and-the-pharmacokinetics-of-multiple-dose-administration-of-warfarin-in-healthy-adult-volunteers-100264264",false,"NCT02719431","Drug-Drug Interaction Study to Assess the Effects of Multiple-Dose Administration of K-877 on the Pharmacodynamics and the Pharmacokinetics of Multiple-Dose Administration of Warfarin in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Subject provides written informed consent before any study specific evaluation is performed.\n* Subject is a healthy adult male or female volunteer between the ages of 18 and 45 years, inclusive.\n* Subject has a body mass index of 18 to 30 kg\u002Fm², inclusive.\n\nExclusion Criteria:\n\n* Subject has clinically relevant abnormalities in the screening or check in assessments.\n* Subject has clinically significant out-of-range PT, INR, activated partial thromboplastin time, fibrinogen, protein C, or protein S.\n* Subject has abnormal prolongation of skin bleeding time at Screening.",true,"ALL","18 Years","45 Years",{"count":48,"type":49},20,"ACTUAL","INTERVENTIONAL",[52],"PHASE1","The purpose of this study is to assess the effects of K-877 on the pharmacodynamics and the pharmacokinetics of warfarin in healthy adults volunteers.",[55],"Healthy","COMPLETED","2016-03-21",{"date":59,"type":60},"2016-03-25","ESTIMATED",{"date":62,"type":11},"2016-01",{"date":64,"type":49},"2016-02",{"name":5,"class":6},1]